• Prof. Lorenzo Brunetti: Artificial intelligence and ethical dilemmas in hematology

    esanum talks with Prof. Brunetti about AI in medicine, its ethical implications and physicians' approach to this tech revolution.

  • Prof. Antonio Almeida: Academic knowledge disseminates in no time

    New technologies have transformed haematology almost completely. Gene-editing and small molecular agents become available to patients without greater delays.

  • Prof. Maria Chiara Bonini: Gene therapy applied to immunotherapy

    esanum talks with Prof. Bonini about her research projects, her EHA board role and the prospects for young hematologists who wish to engage in research.

  • DA-EPOCH-R: less toxic than CODOX-M/R-IVAX in high-risk Burkitt lymphoma

    Trial results show equal DA-EPOCH-R efficacy to CODOX-M/R-IVAX as first-line treatment in patients, but less toxicity.

  • PI3Kδ inhibitor leniolisib improves symptoms in patients with APDS/PASLI

    Leniolisib is safe, increases naïve B cells, decreases lymphadenopathy and spleen size, and improves cytopenia in APDS/PASLI.

  • Early ASCT to triplet therapy improves PFS in multiple myeloma

    Early ASCT in lenalidomide / bortezomib / dexamethasone therapy followed by lenalidomide maintenance, significantly improves PFS for newly diagnosed MM

  • Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin

    Exa-cel gene-editing therapy is associated with increase in foetal and total haemoglobin in transfusion-dependent β-thalassemia or severe sickle cell disease patients.

  • Triple-therapy improves PFS in fit, previously untreated CLL patients

    Phase-3 trial shows improved PFS with venetoclax/obinutuzumab/ibrutinib therapy in fit, untreated patients with chronic lymphocytic leukaemia.

  • Hack Your Care opens the doors to innovation in health

    A new platform connects the spheres of medical care and health innovation. It allows caregivers to find assignments with innovation actors, including companies.

  • No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics

    CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in AML patients with adverse cytogenetics.

  • Luspatercept benefits transfusion-dependent β-thalassemia patients after 3 years

    Continued treatment with luspatercept, for up to 3 years, allowed more patients to experience a reduction in red blood cell transfusion burden.

  • New subtypes of oncogenic deregulation in childhood T-ALL uncovered

    Large-scale whole-genome sequencing, whole-exome sequencing, and RNA-expression profiling found new T-cell acute lymphoblastic leukaemia subtypes.

  • Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML patients

    OS improves when combined with standard induction and consolidation therapy, and as continuation therapy as a single agent for up to 3 years in patients.

  • Axi-cel superior in older patients with relapsed/refractory large B-cell lymphoma

    A subgroups analysis of patients aged 65 years or older in ZUMA-7 demonstrated axi-cel to be superior to standard-of-care for second-line treatment.

  • Caplacizumab is safe and effective in patients with iTTP

    Data from the post-HERCULES trial support caplacizumab's long-term safety and efficacy, including its repeated use, in patients with acquired or immune-mediated thrombotic thrombocytopenic purpura.

  • Abscopal response observed in HL patients who failed on anti-PD treatment

    Treatment with nivolumab and radiotherapy at a single lesion is well tolerated and leads to an abscopal response in the majority of the relapsed/refractory HL cases.

  • Momelotinib: rapid and sustained improvement in haemoglobin for myelofibrosis patients

    The phase 3 MOMENTUM trial show a significant improvement in symptoms, spleen size, and anaemia measures with momelotinib over danazol.

  • Carfilzomib, lenalidomide, and dexamethasone outperforms lenalidomide in MM

    Phase-3 ATLAS trial shows the post-transplant maintenance therapy benefit of carfilzomib, lenalidomide, and dexamethasone over lenalidomide.

  • Pan-clonal score predicts first-line treatment response in AML

    AML has a high patient-to-patient variability in treatment response. Pharmacoscopy allows ex vivo functional drug-response profiling of (tumour) cells enabling tailor-made treatment.

  • How DNA diagnostics began: The Colin Pitchfork murder case

    In 1983 and 1986, the British police struggle with two murders. Until geneticist Dr. Alec Jeffreys brought us RFLP. Genetic fingerprinting was born.

  • 1 |
  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |